Biofilm-forming Staphylococcus epidermidis expressing vancomycin resistance early after adhesion to a metal surface.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

Vancomycin Resistance*/drug effects; Biofilms/*growth & development ; Metals/*pharmacology ; Staphylococcus epidermidis/*physiology; Bacterial Adhesion/drug effects ; Biofilms/drug effects ; Colony Count, Microbial ; Fluorescence ; Staphylococcus epidermidis/drug effects ; Surface Properties ; Time Factors ; Vancomycin/pharmacology

We investigated biofilm formation and time of vancomycin (VCM) resistance expression after adhesion to a metal surface in Staphylococcus epidermidis. Biofilm-forming Staphylococcus epidermidis with a VCM MIC of 1 μg/mL was used. The bacteria were made to adhere to a stainless steel washer and treated with VCM at different times and concentrations. VCM was administered 0, 2, 4, and 8 hours after adhesion. The amount of biofilm formed was evaluated based on the biofilm coverage rates (BCRs) before and after VCM administration, bacterial viability in biofilm was visually observed using the fluorescence staining method, and the viable bacterial count in biofilm was measured. The VCM concentration required to decrease BCR significantly compared with that of VCM-untreated bacteria was 4 μg/mL, even in the 0 hr group. In the 4 and 8 hr groups, VCM could not inhibit biofilm growth even at 1,024 μg/mL. In the 8 hr group, viable bacteria remained in biofilm at a count of 10(4) CFU even at a high VCM concentration (1,024 μg/mL). It was suggested that biofilm-forming Staphylococcus epidermidis expresses resistance to VCM early after adhesion to a metal surface. Resistance increased over time after adhesion as the biofilm formed, and strong resistance was expressed 4-8 hours after adhesion.

Anal Bioanal Chem. 2007 Jan;387(2):399-408. (PMID: 16955256)
J Antimicrob Chemother. 2006 Apr;57(4):589-608. (PMID: 16507559)
J Bone Joint Surg Am. 2008 Aug;90(8):1751-8. (PMID: 18676908)
Clin Infect Dis. 2009 Aug 1;49(3):325-7. (PMID: 19569969)
J Orthop Res. 2009 Oct;27(10):1361-5. (PMID: 19396814)
J Orthop Sci. 2009 Nov;14(6):769-75. (PMID: 19997825)
Microsc Res Tech. 2010 Jul;73(7):662-4. (PMID: 20572203)
Future Microbiol. 2011 Nov;6(11):1329-49. (PMID: 22082292)
Int J Artif Organs. 2013 Feb;36(2):105-12. (PMID: 23280080)
Biomatter. 2012 Oct-Dec;2(4):176-94. (PMID: 23507884)
J Bone Joint Surg Am. 2013 Dec 18;95(24):2223-9. (PMID: 24498639)
Folia Microbiol (Praha). 2014 Jul;59(4):283-8. (PMID: 24390796)
J Intern Med. 2014 Aug;276(2):111-9. (PMID: 24605880)
Clin Microbiol Infect. 2006 May;12 Suppl 3:93-101. (PMID: 16669932)
J Spinal Disord. 2000 Oct;13(5):422-6. (PMID: 11052352)
Mol Microbiol. 2001 Jun;40(5):1215-26. (PMID: 11401724)
Lancet. 2001 Jul 14;358(9276):135-8. (PMID: 11463434)
Nature. 2002 Apr 18;416(6882):740-3. (PMID: 11961556)
Antimicrob Agents Chemother. 2003 Sep;47(9):2997-3001. (PMID: 12937012)
J Bone Joint Surg Br. 2004 Sep;86(7):962-5. (PMID: 15446518)
Annu Rev Microbiol. 1984;38:339-57. (PMID: 6388496)
J Bone Joint Surg Am. 1985 Feb;67(2):264-73. (PMID: 3881449)
Chemotherapy. 1992;38(5):286-90. (PMID: 1286571)
J Clin Microbiol. 1999 Jun;37(6):1771-6. (PMID: 10325322)
Science. 1999 May 21;284(5418):1318-22. (PMID: 10334980)
Antimicrob Agents Chemother. 2005 Jul;49(7):2612-7. (PMID: 15980327)
Clin Orthop Relat Res. 2005 Aug;(437):7-11. (PMID: 16056019)
Nature. 2005 Aug 25;436(7054):1171-5. (PMID: 16121184)
Antimicrob Agents Chemother. 2006 Jan;50(1):55-61. (PMID: 16377667)
J Orthop Sci. 2006 Jan;11(1):46-50. (PMID: 16437348)
Antimicrob Agents Chemother. 2007 May;51(5):1656-60. (PMID: 17353249)

0 (Metals)
6Q205EH1VU (Vancomycin)

Date Created: 20150325 Date Completed: 20160519 Latest Revision: 20181113

20231215

PMC4329865

10.1155/2015/943056

25802873